DNLI Q1 2018 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$641,000

Gross Profit

$641,000100.0% margin

Operating Income

-$26M-4016.8% margin

Net Income

-$24M-3693.9% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$33M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$614M

Total Liabilities

$75M

Stockholders' Equity

$539M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$641,000	$0	—
Gross Profit	$641,000	$0	—
Operating Income	-$26M	-$22M	-18.4%
Net Income	-$24M	-$21M	-11.1%